A Record-Scale Outbreak Is Still Growing
The Democratic Republic of the Congo is facing one of the most severe Ebola outbreaks in recorded history. As of July 13, 2026, DRC health authorities reported 1,963 confirmed Ebola cases and 719 related deaths, according to the European Centre for Disease Prevention and Control (ECDC). The death toll represents a case fatality rate of approximately 37%, consistent with the Bundibugyo strain's known range of 30 to 40%.
On July 13, 2026, the U.S. government signed an Order extending entry restrictions for certain foreign nationals who have been in DRC, Uganda, or South Sudan within the prior 21 days. The Order remains in effect for 30 days. A U.S. citizen working for a humanitarian organization in DRC tested positive for the Bundibugyo virus on July 10 and was medically evacuated to Germany for treatment on July 13, the second such American evacuation during this outbreak.
Why This Matters
This outbreak matters to U.S. readers for two interconnected reasons. First, no approved vaccine or specific treatment exists for the Bundibugyo strain of Ebola. The two licensed Ebola vaccines — Ervebo and the Mvabea/Zabdeno regimen — both target the Zaire ebolavirus, a different species. Their effectiveness against Bundibugyo virus has not been clinically established, meaning response efforts are relying on isolation, contact tracing, and supportive care rather than vaccination.
Second, the virus has already reached multiple countries. Uganda has confirmed 20 cases linked to travel from DRC. France confirmed an imported case in June 2026. And now two U.S. citizens have been evacuated for treatment in Germany. U.S. entry screening is actively occurring at airports for travelers arriving from DRC, Uganda, and neighboring South Sudan.
The CDC currently recommends avoiding non-essential travel to multiple provinces in DRC, including Ituri, North Kivu, South Kivu, Tshopo, and Haut-Uele.
What We Know So Far
The current outbreak was first declared by the DRC's Ministry of Public Health on May 14, 2026, after genomic sequencing confirmed Bundibugyo ebolavirus in Ituri Province. On May 16, 2026, the World Health Organization declared the outbreak a Public Health Emergency of International Concern (PHEIC) — the highest-level global health alert and only the eighth such declaration in history.
As of July 13, 2026, 736 patients were hospitalized in isolation. Among all cases, 333 individuals have recovered. The 31 new cases reported on July 13 came primarily from Ituri and North Kivu provinces. Ituri remains the epicenter, accounting for 1,772 of the total 1,963 confirmed cases.
Cases have now been reported in five DRC provinces: Ituri, North Kivu, South Kivu, Haut-Uele, and Tshopo — a geographic spread that reflects the challenges of containing an outbreak in a conflict-affected, densely populated region with limited healthcare infrastructure.
Where the Risk Is Highest
Ituri Province in northeastern DRC represents the core of the outbreak, with 608 confirmed deaths among 1,772 cases, according to the ECDC's July 14 update. The province's combination of ongoing armed conflict, limited health facility access, high population movement, and attacks on healthcare workers makes containment especially difficult.
Internationally, Uganda confirmed 20 cases, all linked to travel from DRC. Uganda has reported no new cases since June 21, 2026, according to the WHO. France confirmed one imported case in June 2026. Germany has now received at least two medically evacuated Ebola patients from DRC.
For U.S. readers, CDC is screening travelers arriving from DRC, Uganda, and South Sudan at designated airports. No cases linked to this outbreak have been confirmed on U.S. soil.
What Doctors and Experts Say
The ECDC assessed the likelihood of infection for people living in the European Union as "very low," a conclusion that broadly applies to the general U.S. public as well. However, the agency emphasized that the risk is not zero for travelers to affected provinces or for humanitarian and health workers deployed in the region.
Researchers at the University of Oxford have launched what is described as the world's first Phase I clinical trial of a vaccine specifically targeting Bundibugyo ebolavirus, under the BD-Ebov program. Separately, investigators in DRC have begun the first randomized clinical trial evaluating remdesivir and the monoclonal antibody MBP134, both of which remain experimental for Bundibugyo virus disease, according to The Watchers.
For the general U.S. public, CDC's position is clear: "The likelihood of Ebola spreading to the United States is considered very low."
What the Evidence Shows and What It Does Not
Bundibugyo ebolavirus is the rarest of the four human-pathogenic Ebola species. Before this outbreak, only two prior outbreaks had ever been attributed to the Bundibugyo strain — one in Uganda in 2007 to 2008 involving 149 cases, and one in DRC in 2012 involving 52 cases.
The current outbreak's scale — already at 1,963 confirmed cases — has surpassed all prior Bundibugyo outbreaks combined by an extraordinary margin, making it the third-largest Ebola outbreak in recorded history after the 2014 to 2016 West Africa epidemic and the 2018 to 2020 DRC outbreak.
MedicalDaily Evidence Check
- Outbreak type: Confirmed Bundibugyo ebolavirus, a distinct species from the Zaire strain targeted by existing vaccines
- Total confirmed cases: 1,963 as of July 13, 2026
- Confirmed deaths: 719
- Recoveries: 333
- Patients hospitalized in isolation: 736
- No approved vaccine or specific treatment for Bundibugyo strain
- No confirmed cases in the United States
Who Faces the Greatest Risk
The CDC and WHO identify the following groups as facing the greatest risk related to this outbreak:
- Humanitarian aid workers and healthcare professionals deployed in DRC, Uganda, or neighboring South Sudan
- Travelers making non-essential visits to Ituri, North Kivu, South Kivu, Tshopo, or Haut-Uele provinces in DRC
- Healthcare workers who could potentially treat an imported case without knowing the patient's exposure history
For the broader U.S. population, direct risk remains very low. Ebola does not spread through casual contact, air, or water. Transmission requires direct contact with the bodily fluids of a person who is symptomatic or has died from the disease.
Symptoms and Warning Signs to Watch For
People returning from affected regions should monitor for the following symptoms for 21 days after their last possible exposure:
- Sudden fever
- Severe headache
- Muscle and joint pain
- Weakness and fatigue
- Sore throat
- Vomiting
- Diarrhea
- Rash
- Bleeding or bruising (in later stages)
Symptom onset typically occurs between 2 and 21 days after exposure. Anyone who develops a fever or other symptoms after traveling to DRC, Uganda, or neighboring areas should contact a healthcare provider immediately and disclose their travel history before arriving at a clinic or emergency room. Healthcare facilities can then implement appropriate precautions.
What You Can Do Now
- Do not travel to Ituri, North Kivu, South Kivu, Tshopo, or Haut-Uele provinces in DRC unless travel is essential. The CDC rates travel to these areas as Level 4: Avoid All Travel.
- If you must travel to affected regions , register with the U.S. Embassy's Smart Traveler Enrollment Program (STEP) and carry contact information for the nearest U.S. embassy or consulate.
- Monitor your health for 21 days after returning from any potentially affected area. Track your temperature daily.
- Call ahead to your healthcare provider if you develop fever after returning from DRC, Uganda, or South Sudan — do not walk in unannounced, so the clinic can prepare appropriate infection control precautions.
- Stay updated via the CDC's Ebola Situation Summary , which is updated regularly as new information becomes available.
Cost and Access: What Patients Should Know
Ebola testing is conducted at CDC-authorized laboratories and requires coordination between clinicians, local public health departments, and the CDC's Emergency Operations Center. Patients should not attempt to seek Ebola testing independently — the process is managed through public health channels.
U.S. travelers who become ill abroad can contact the nearest U.S. Embassy or Consulate for emergency medical assistance. The U.S. Department of State's overseas citizen services can assist with medical referrals and, in severe cases, coordinate medical evacuations for American citizens.
What Happens Next
WHO, ECDC, and CDC are all continuing active monitoring of the outbreak. Oxford's Phase I Bundibugyo vaccine trial represents the most significant near-term development in countermeasure research, though results from a Phase I trial do not confirm efficacy and the pathway to a licensed vaccine remains long.
CDC will continue airport-based screening of travelers arriving from DRC, Uganda, and South Sudan. The U.S. entry restriction Order, signed July 13, runs for 30 days, with potential renewal if outbreak conditions persist.
MedicalDaily will update this story as new case counts, research developments, and travel guidance changes are released.
The Bottom Line
This Bundibugyo Ebola outbreak is the largest of its kind in history and represents a genuine global health emergency. For most U.S. residents — especially those with no plans to travel to affected regions — direct risk remains very low. For humanitarian workers, global health professionals, and travelers with reasons to visit DRC or neighboring countries, the CDC's current recommendation is clear: avoid non-essential travel to the most affected provinces. If you are returning from the region and develop a fever within 21 days, contact a healthcare provider immediately and disclose your travel history.
